Experimental prostate cancer combo trial halted early

NCT ID NCT05733351

Terminated Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a new immunotherapy drug called vudalimab (XmAb20717) alongside standard treatments for men with metastatic castration-sensitive prostate cancer. The study aimed to check safety and early signs of effectiveness. However, the trial was terminated early after enrolling only 4 participants, so no conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vudalimab (XmAb20717) plus standard of care (abiraterone, enzalutamide, or docetaxel)
What this could lead to: If successful, this could point toward a new combination therapy that helps control metastatic prostate cancer for longer.
What could go wrong: This was a very early, small Phase 1 trial that was terminated early with only 4 participants. It is too early to know if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-SENSITIVE PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-SENSITIVE PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.